Everton FC could be set to join the growing list of sports clubs teaming up with CBD companies in a deal which could kick-start a cannabis sponsorship revolution in the UK.
It was reported last month that Swiss CBD firm Swissx is looking to become the shirt sponsor of the Merseyside club in a multi-million-pound deal; amid rapid growth in the cannabis products market.
The UK CBD market will be worth almost £1bn per annum by 2025, according to the Centre for Medicinal Cannabis.
With such growth comes bigger marketing budgets and the opportunity for CBD firms to buy space on sleeves and chests usually the preserve of gambling, global financial services and beer brands.
While High Street health food stores maybe off-limits due to COVID-19, online sales of CBD are buoyant.
As we reported here, partly this is down to people seeking a general fitness or wellbeing boost at a time of looming healthcare danger.
This added momentum in sales, plus the fact that many sports clubs are facing financial turmoil until normality is restored and will need every ounce of sponsorship they can muster, could create a perfect storm of opportunity for CBD firms.
A YouGov poll last August found that one in 10 UK consumers use products with legal cannabis extracts – but also that 28 per cent of Brits are considering them.
Sponsoring mass market sport could help to convert these floating voters. Then there is the normalisation, destigmatising factor.
For all the progress of the cannabis products industry and the vast body of evidence supporting CBD’s worth, old misconceptions linger on.
For example, a poll published last December found that a fifth of Brits believe CBD is illegal, while 64 per cent do not realise it can be bought in shops.
“Our prejudices and fears towards cannabis have been ingrained over many years”, said Nicola Webster of Vape UK, which commissioned the poll.
As Guy Coxall, chairman of hemp policy think tank Hemptank pointed out at the last big UK cannabis industry event pre-lockdown, there were once as many as 200 cannabis-based products available at the British pharmacy.
But the influence of the US eventually won out. Across the pond, policy had been shaped from the 1930s by Federal Bureau of Narcotics chief Harry Anslinger, and his demonisation of cannabis.
Writing in the Times Literary Supplement, David Nutt, the Edmond J Safra Chair in Neuropsychopharmacology at Imperial College London, explains: “Cannabis continued as a medicine in the UK, in direct conflict with the international policy driven by the 1934 League of Nations claim that it had no medicinal value.
“The international anti-cannabis stance was consolidated in 1961 under the UN Convention on Narcotic Drugs, where cannabis was put in Schedule 1 along with heroin. Schedule 1 drugs were defined as those with no medicinal value and possessing of great harms. But the UK stood against this policy, and continued to allow both drugs to be prescribed.
“A decade of political pressure from the USA, which demanded complete prohibition internationally, ensued, and in 1971 the UK government caved in and eliminated cannabis (though not heroin) as a medicine under the Misuse of Drugs Act.”
Of course cannabis medicine, via prescription, and CBD as part of a burgeoning health and wellbeing industry, are both legally accessible in the UK (although the former has not been forthcoming via the NHS).
But if misconceptions and fears among the British public are indeed deep-rooted then sport could be the attention-grabber needed to put them to bed.
Certainly in our interviews with cannabis product users, we regularly encounter people who feel there is a stigma and often ask to remain anonymous when we publish their stories. Sports advertising could blow away these taboos and get even more people talking about the benefits of CBD and other compounds.
It would give more airtime to the positivity of CBD and cannabis-based wellness generally, in a nation where certain influential newspapers continue to publish headlines to the contrary, with little substance or balance: like ‘One dose of THC can cause psychosis in people with no mental health history’ (debunked here) and ‘Legal cannabis oil sold in British health shops can get users high and make it dangerous to drive’ (based on a study using an astronomical dose of CBD from a university that has ignored Cannabis Health’s request for an interview).
Sports could be a powerful amplifier of the cannabis-products industries. Research published by the Journal of Advertising Research based on 52 academic papers shows that embedding ads within sport creates an emotional bond with brands, that can ultimately lead to sales.
Meanwhile, more and more elite athletes are using cannabis products for their anti-inflammatory qualities, as well as their ability to help speed up muscle recovery and improve sleep.
In 2018, the World AnitDoping Agency removed CBD from its Prohibited List, meaning athletes were free to use them.
This was a big step in terms of marketing opportunities, meaning cannabis companies could get sports stars to use their products, while promoting them at the same time.
Despite this positive move, there are relatively few athletes who openly use CBD, with combat sports being among the keenest embracers of such products.
Aurora Cannabis agreed a deal with UFC in 2019 which aimed to conduct research into how using CBD can be beneficial for athletes in terms of how their muscles recover after exercise.
This then led to fighter Alexey Oleynik becoming one of the world’s first cannabis sponsored athletes after he agreed a partnership with TFMG Alternative Harvest ETF MJ.
MMA (mixed martial arts) is another combat sport to really take to the cannabis industry, with Bellator (the world’s leading MMA league) announcing in 2019 that they would be entering a multi-million-dollar partnership with hemp company cbdMD which would give it branding rights to the sports fighting cage.
The president of cbdMD set out the aims of the deal in a press release, saying “our partnership with Bellator will facilitate a unique opportunity to educate athletes and fans about the many benefits of CBD”.
Other examples of cannabis products working their way into top-level sport come from the fairways of elite golf.
According to Golf Digest, between 15-20 leading players routinely use CBD to help their performance, with Billy Horschel being one of the few to openly admit to using these remedies.
Motorsport has also taken to the cannabis industry, with some F1 and MotoGP athletes now proudly displaying CBD company logos on their vehicles.
Cannabis/tech organisation WeedMaps now sponsors around 20 motorsports athletes, meanwhile.
Furthermore, Israel’s rugby side was sponsored by UK CBD business Provacan in 2019, making it the first international side in any sport to endorse a cannabis company.
Another instance of this is US baseball team the Portland Pickles, striking an exclusive partnership with Lazarus Naturals in 2019.
The Las Vegas Lights also made the news when it became the first football team in the US to associate itself with a cannabis brand.
The sponsorship involves Two Roots, which produces cannabis infused beer that contains THC.
Closer to home, Birmingham City FC entered a deal with Green Monkey – an organisation which produces CBD and hemp-based drinks – in which it agreed to sell products at the club’s ground.
Everton FC could soon follow in Birmingham’s footsteps if its deal with Swissx goes through, although press mutterings by the CBD company have suggested there is some reluctance from the football club’s side of the deal. And Swissx has form in dealing with this type of resistance.
Last year it attempted to acquire the naming rights of FC Barcelona’s Camp Nou stadium, but the club ultimately rejected the deal.
Chairman of the firm Alki David criticised the football club, saying it needed to embrace the industry in the same way UFC has.
Speaking to BBC Sport about the Barcelona deal, David said: “The bottom line is they are being really precious about this being a cannabis brand.
“But they’ve got to realise that UFC embraces cannabis, and other sporting leagues accept cannabis. My brand is not a fucking marijuana brand, it’s a wellness CBD brand based on health, not based on recreation.”
Unfortunately for cannabis companies looking to invest into the sporting market, this reluctance to endorse CBD products is mirrored in other elite sporting leagues outside the US.
Perhaps a deal between Everton FC and Swissx could be the catalyst for more at the top level of European sport.
There is clearly an ambition in the cannabis products industry to move into sports sponsorship, underlined by rapid growth of the sector. It is only a matter of time before these aspirations are realised on a vast scale, especially as other markets falter in the ensuing global recession.
First Medical Cannabis Awareness Week launches in the UK – how you can get involved
The first Medical Cannabis Awareness Week is calling for access to NHS prescriptions two years on from the landmark law change.
Taking place from 1-8 November 2020 the inaugural Medical Cannabis Awareness Week (MCAW) will bring together patients, doctors, advocates and organisations to call for fair access to medical cannabis on the NHS.
On 1 November 2018, the law changed to allow UK patients access to medical cannabis. But since then, only a handful of prescriptions have been issued by the NHS.
Patients are struggling to fund private prescriptions – costing several hundreds of pounds a month – and up to 1.4 million people are forced to turn to the illegal cannabis market.
Most patients prescribed medical cannabis live with chronic pain, neurological or psychiatric conditions, such as fibromyalgia, multiple sclerosis, epilepsy, anxiety & PTSD – yet many continue to face stigma in their day-to-day lives and from healthcare professionals when trying to access this treatment.
Launched by PLEA (Patient-Led Engagement for Access) – a community of medical cannabis patients and advocates – throughout the week patients from across the UK will share their stories about the life-changing impact of medical cannabis and their difficulties in accessing a prescription.
Individuals and organisations from across the sector will take part in online events including a tour of a legal cannabis growing facility, and conversations with patients and doctors.
PLEA advocacy director Lucy Stafford took addictive opiate-based painkillers nearly every day of her teenage years to cope with the debilitating symptoms of the connective tissue disorder called Ehlers Danlos Syndrome.
“I had to drop out of school and live with the horrendous side effects. I was a shadow of myself,” she said.
“When I was prescribed medical cannabis, it changed everything. I’ve learnt to walk after years using a wheelchair and now attend university – I’ve got my life back. All patients in need should have the same chance to live a better quality of life – we need NHS access.”
The PLEA Community will host MCAW during the first week of November each year.
As part of the awareness week, people are encouraged to talk about medical cannabis with their friends and family, record and share their own story, write to their MPs and even play medical cannabis bingo (have you been called a stoner when talking about your medicine? Has anyone ever suggested you’re just after a legal high?)
“It’s time to end the inequality and ensure everyone who needs it has the opportunity to benefit from medical cannabis treatment,” said Abby Hughes, PLEA outreach director.
“During MCAW, we’re calling for fair access, we’re promoting medical cannabis education for all and we’re directly addressing the stigma faced by patients. We want people to have conversations about cannabis, ask questions and be open-minded.
“Cannabis medicines are changing people’s lives around the world. In the UK, people are forced to pay privately, and it’s not right. Medical cannabis is keeping children with severe forms of epilepsy alive, and it’s allowing people with chronic illnesses and conditions to live normal lives.”
PLEA advocates for quality of life with medical cannabis, enabling patients to access their medicine free from stigma, geographical inconsistencies, and financial barriers and supports research into the safety and efficacy of cannabis-based medicinal products, to enable evidence-based prescription for all.
Dr Mala Mawkin, head of market development at Cellen Health and advisory board member at PLEA added: “Even though doctors have been able to prescribe Cannabis based Medicinal Products since 2018, healthcare professionals are still not equipped with the knowledge and tools to prescribe in the UK.
“We have made huge progress to be able to have pharmaceutical-grade THC/CBD medicines for patients that are cheaper and safer than the illicit market. The next steps are to invest in research, medical education and address the stigma faced by patients.
“Events during MCAW are here to show patients and healthcare professionals it is essential to talk openly about medical cannabis to address the unmet clinical needs of people living with chronic conditions.”
You can join advocates and organisations to share your PLEA on social media using the hashtag #MCAW2020
Follow @PLEA_community on Twitter and Instagram.
For more information and full programme visit www.medicalcannabisweek.org.uk
‘I moved to Spain to get access to medical cannabis’
Award-winning campaigner Alicia Maher is doing a PhD in the regulation of medical cannabis in Ireland, but she’s had to move abroad to access her life-changing medication.
Alicia Maher has one of those unimaginable stories. When she went into hospital to have her tonsils removed at the age of 17, she never expected to leave more than six months later with a lifelong disability.
After what should have been a fairly standard procedure she suffered hemorrhages in her throat and had to undergo several more surgeries. Then, while recovering in hospital she started bleeding from her bowel and doctors discovered Alicia had ulcerative colitis, a form of inflammatory bowel disease.
Things escalated quickly and one night her large intestine burst and she was rushed into emergency surgery.
The intestine had to be removed and Alicia woke up with an ileostomy bag.
“This was 2001 – I hadn’t heard of ulcerative colitis or crohn’s at the time,” she says now.
“I didn’t even know what an ileostomy bag was, I just woke up with it. For years I went to counselling and to try and accept it.”
The procedure was always supposed to be reversed, but in 2006 precancerous cells were discovered in her rectum and it had to be removed, meaning the stoma was permanent.
It was following further complications after surgery, that the chronic pain started.
“After that operation was the first time I started having chronic pain and it never went away,” she says.
After six years of being prescribed painkillers and patches Alicia was referred to a pain specialist who discovered that the cause of her pain was a broken coccyx.
She was offered surgery, steroid injections, and more medication. And then, if that wasn’t enough, in 2015 she developed sciatica.
By this point Alicia was on up to 30 tablets a day, from paracetamol to heavy opioids such as tramadol.
“They just kept adding more and more medication and it went on like that for years,” she says.
“The side effects of the medication had become absolutely horrendous. I missed a lot of time off university because as soon as I got up I’d have to take 10 opioids, and I’d be asleep again within half an hour.”
She adds: “It really affected my breathing so I couldn’t really do much. I had absolutely no quality of life.”
In November 2018 Alicia tried cannabis for the first time when a friend from New York sent her some oil and a vape cartridge.
“It worked straight away for the pain and I decided there and then that I was going to come off the medication,” she says.
“I didn’t know what was going to happen or whether it was going to get rid of the pain altogether, but I slowly started to cut down on the tablets.”
After she had been able to reduce her medication by half, Alicia broached the subject with her doctor, who was supportive and agreed to apply for a ministerial license to prescribe medical cannabis.
However the licence needed to be signed off by her consultant, who at the exact same time left the public health system to go private.
Alicia explains: “I no longer had a pain consultant and because I’m a public patient it took until January 2019 to be referred to another one.”
Although he agreed to sign it off, the process had taken so long that in November 2019 Alicia and her husband left their home in Limerick – where they were both studying PhDs – to move to Spain, where she could more easily access her medication.
“At the time I was just buying cannabis illegally and sometimes it would work and sometimes it wouldn’t. I never knew what strain I was getting or how strong it was,” she says.
“We knew that they had cannabis clubs in Spain and that I’d be able to go in and buy it, so we agreed that we would move until I got the licence through.”
Alicia continues: “It was really hard, we literally had to leave everything, our apartment, our family and friends.
“It’s worth it, knowing that we can access cannabis here but there’s a huge downside. We expected to be home a lot sooner.”
Alicia’s licence was approved in May this year, but due to the coronavirus outbreak the couple have been unable to return to Ireland.
“The doctor advised me not to travel due to my underlying health conditions. Now we don’t know when we’ll be able to get home,” she says, desperate to return to Limerick and finish her PhD thesis on the regulation of medical cannabis in Ireland.
Inspired by her own battle, Alicia hopes it will help influence legislation around medical cannabis in the country.
Ireland launched the Medical Cannabis Access Programme in June 2019, allowing consultants to prescribe to patients that have failed to respond to treatments for spasticity associated with MS, intractable nausea and vomiting associated with chemotherapy and severe, refractory epilepsy.
But so far no one has been prescribed cannabis through the scheme.
Patients can also apply for a ministerial licence, as Alicia has, but often the Government won’t refund the costs, leaving them to pay for it themselves.
“First and foremost I’d like to see the Medical Access Programme up and running for patients who are waiting and I’d like it to be expanded for other medical conditions,” says Alicia.
“Chronic pain currently isn’t included, but I’d like to see it go even further than that, where there’s evidence from other countries about its efficacy for certain conditions.”
She adds: “I’d love for my PhD to have some influence on the programme – my second chapter is showing the medical evidence that is available for a wide range of conditions.”
Alicia has organised a number of medical cannabis conferences, including an event for over 200 people at the University of Limerick last year, attended by leading politicians and prominent campaigners such as Alfie Dingley’s mum Hannah Deacon and Vera Twomey.
She continues to advocate for wider access and acceptance, even winning a Cannabis Award for Outstanding Patient this summer.
“It was really nice to be recognised, but it’s just sad to see that there has still been no progress,” she says.
To say Alicia’s life has been shaped by medical cannabis is an understatement. Does she ever wish things had taken a different course?
“I struggled with it for many years, but I’m happy now with how things have turned out,” she adds.
“Since I started taking cannabis it’s like I have returned to my old self, to how I was before I was sick.”
Now she’s just holding out until she can return home.
“It saved Zak’s life, but we’re not out of the woods yet”
Aged 15, Zak was given six to 12 months to live, but eight years later his thirst for life is greater than ever, says dad, Benedict Lamb.
No parent wants to hear a doctor say there is nothing more they can do for your child. Zak Lamb was 15 at the time, having been diagnosed with Dravet Syndrome, a rare form of epilepsy he had been suffering seizures since he was just 11 months.
Doctors tried various cocktails of drugs to keep it under control, but Zak even at his best he was still experiencing up to 16 seizures a night.
By 15 his condition had begun deteriorating rapidly. His seizures became more frequent and severe, he suffered damage to his brain and nervous system as a result and needed the use of a wheelchair.
Eventually Zak’s consultant delivered the devastating news there was nothing left to try.
“The NHS told us that he had six to 12 months to live which I got in writing,” says Zak’s dad 52-year-old Benedict Lamb.
“As soon as a doctor writes a letter saying that your child is not going to not make it, certain mechanisms kick into place.”
The Make a Wish Foundation reached out and funded a final holiday for the family to make some lasting memories.But Benedict wasn’t ready to say goodbye.
“At that point, I didn’t even know what CBD was, I just Googled epilepsy treatments and it came up,” he says.
“I started to do some more research and discovered Epidiolex.”
In his own words, he got lucky. GW Pharmaceuticals was just about to start its first trial for the drug on patients in the United States.
He happened to have a friend who knew CEO Justin Gover and managed to get him a phone call with the pharmaceutical giant.
Unprecedentedly, by the end of the call he had agreed to write a license specifically for Zak.
“A pharmaceutical company would normally licence a drug for a territory or a country,” Benedict explains.
“It’s very unusual for them to write a licence for an individual – but they did that for Zak.”
There was one catch though, he had to sign a non-disclosure agreement, and wasn’t allowed to speak about it for the first year.
A filmmaker and art director, Benedict was making a documentary for Dravet Syndrome UK at the time, but was forced to keep his son’s progress from other parents in similar situations.
“Back then Epidiolex was the holy grail, it was the drug on the horizon and everyone wanted it,” he says.
“It was difficult interviewing all these parents with very sick children and not being able to tell them that Zak was on it.”
Epidiolex was made available on the NHS in the UK for children with rare and severe forms of epilepsy in 2019.
However, many parents have since found it to be ineffective for their child, or report that their progress has plateaued after several months on the treatment.
Zak’s was a rare success story, so much so, his case was used by GW Pharmaceuticals’ in their application for FDA approval of the drug.
After a year of having to keep quiet, Benedict was suddenly asked to speak to anyone and everyone about the benefits of medical cannabis.
“Zak was patient number one and he was very rare at that point,” he says.
“There were another hundred children on the trial and out of 101 children, Zak’s was by far the most successful case.”
Benedict continues: “He went from having between 12 -16 seizures every night to having one to two seizures every few days, in less than a week.
“We are lucky in a way, compared to where we were, Epidiolex is a success and it hasn’t plateaued off which is one of the biggest fears for most people in this situation.”
Now 23, Zak still has seizures, is reliant on a wheelchair and has autism, but since he started on the drug he has been able to attend St Piers College for young epilepsy sufferers and has continued to make improvements.
“CBD has been very positive for Zak,” says Benedict.
“His awareness has grown, we’ve noticed that his interactions with the family, his carers, teachers and other students have greatly improved, as has his vocabulary, attention span, eye contact, his desire to socialise, and the number of hours he is awake every day.
“It saved Zak’s life, he was dying and now eight years on he is doing really well – but we’re not out of the woods.”
Of course, with every seizure he experiences putting Zak’s life at risk, Benedict’s ultimate aim is for his son to be seizure-free.
“Every time you have a seizure, it comes with the risk of death or causing more damage to the nervous system or brain,” he says.
“We’re in a much better place than we were, but Zak hasn’t got any worse or any better. The goal for any parent is to get your child to the point where they have no seizures at all.
“That way the risk of mortality is greatly reduced, their development will come on – and of course, the whole family will be much happier and sleep better.”
As a member of the End Our Pain campaign, Benedict acknowledges the relatively privileged position he is in, in not having to find thousands of pounds each month to fund a private prescription of full extract cannabis.
But he is no stranger to the fear that many of the parents feel – that a treatment keeping their child well, will be taken away.
Zak is due to try a new oil soon, containing higher levels of THC, which they hope will further reduce his seizures and improve his quality of life.
While it is generously being funded by the company for the first six months, after that it will be up for review and Benedict may find himself in the unimaginable position of balancing his family’s livelihood with his son’s life
“If Zak does well on it, there’s always a worry that after six months they will turn around and it’s now ‘X’ amount,” he says.
“It’s a fear that a lot of the other parents have, that when they start running out of money they will have to swap to a cheaper oil and their child will endup back in hospital.
“Juggling that financial stress against your child’s health is a horrible balance to be making, and the only reason they are having to make it is because Matt Hancock failed to keep his promise.”
The health secretary told campaigners last year that he would leave ‘no stone unturned’ in efforts to expand access to medical cannabis, but despite this no more NHS prescriptions have been issued.
Last month, Benedict was among several End Our Pain parents to hold public vigils outside UK health authorities across the country, demanding the Government help fund these children’s prescriptions until they become available on the NHS.
“The bottom line is that we all want the same thing,” he adds.
“For full extract medical cannabis to be prescribed for free on the NHS.”
- ‘NHS asking children to come off meds for clinical trials could kill them’
- First Medical Cannabis Awareness Week launches in the UK – how you can get involved
- How Europe’s first medical cannabis tracking app could revolutionise care
- Isle of Man to set ‘benchmark’ for global cannabis sector
- ‘I moved to Spain to get access to medical cannabis’
- Italy classes CBD as a narcotic in ‘laughable’ move
News3 months ago
NHS lines up cannabis medicine manufacturing
Case Studies7 months ago
CBD oil and fibromyalgia – a case study
Feature4 months ago
Medical cannabis could help long-term effects of COVID-19, says David Nutt
Insight2 weeks ago
I’ve gone from a wheelchair to walking thanks to cannabis
News1 month ago
Mum of three-year-old with ‘one in a million’ condition fights for medical cannabis funding
Industry2 months ago
Building America’s biggest hemp empire
News1 month ago
“I’m not a bad person” – chronically ill woman convicted of growing medical cannabis
Industry2 weeks ago
UK firm aims to become world-leading medical cannabis producer